(Reuters) – Teva Pharmaceuticals (TEVA.N) is in talks to contribute over $15 billion worth of drugs as part of a settlement to resolve lawsuits alleging it helped fuel the U.S. opioid crisis, a source familiar with the matter told Reuters on Wednesday.
The news follows media reports that major drug distributors McKesson Corp (MCK.N), AmerisourceBergen Corp (ABC.N) and Cardinal Health (CAH.N) are discussing with governments to settle thousands of opioid-related lawsuits for $18 billion.
The companies, including Teva, are all defendants in a landmark trial set to begin in federal court in Cleveland, Ohio, on Oct. 21, which will be presided over by U.S. District Judge Dan Polster, who has long pushed for a global settlement of the litigation.
Teva did not immediately respond to Reuters’ request for comment.
Reporting by Tamara Mathias in Bengaluru; Editing by Shinjini Ganguli